This is a 3-year, pharmacologically non-interventional study to evaluate OCT as an outcome
measure in patients with relapsing remitting multiple sclerosis (RRMS).
Approximately 350 RRMS patients, either untreated or treated with an approved MS
disease-modifying therapy and approximately 70 reference subjects without ophthalmologic or
neurologic disease are enrolled. No study medications are provided. Patients on
disease-modifying therapy are treated according to the local prescribing information. For
each MS patient and each reference subject, the study consists of Screening (up to 1 month),
Baseline, and a 36-month longitudinal data collection phase. Eligibility will be confirmed